Imalia started a multicenter, randomized, double blind, placebo controlled pilot study in India to evaluate safety and efficacy of orally administered IMA001 in sickle cell disease patients. A total of 170 patients will be included in the study. The treatment duration is 90 days. The primary end point is to check the safety and tolerance of the orally administered IMA001. Secondary endpoints are intended to evaluate the efficacy of IMA001, in particular by evaluating hematological parameters associated with anemia and hemolysis and patient functioning and well-being through a questionaire related to physical pain, sleep, and the emotional impact of SCD.